Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:EMH CVE:IGX NASDAQ:PMN CVE:RUA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPMNPromis Neurosciences$10.68+1.3%$10.73$6.27▼$39.75$94.52M-0.1918,015 shs20,376 shsRUARua GoldC$1.33+4.7%C$1.33C$0.55▼C$1.50C$111.89MN/A196,402 shs284,158 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PMNPromis Neurosciences+1.33%+6.27%-2.73%-38.73%-13.52%RUARua Gold0.00%0.00%0.00%0.00%+93,661,871.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPMNPromis Neurosciences$10.68+1.3%$10.73$6.27▼$39.75$94.52M-0.1918,015 shs20,376 shsRUARua GoldC$1.33+4.7%C$1.33C$0.55▼C$1.50C$111.89MN/A196,402 shs284,158 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PMNPromis Neurosciences+1.33%+6.27%-2.73%-38.73%-13.52%RUARua Gold0.00%0.00%0.00%0.00%+93,661,871.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health Therapeutics 0.00N/AN/AN/AIGXIntelGenx Technologies 0.00N/AN/AN/APMNPromis Neurosciences 2.60Moderate Buy$26.50148.13% UpsideRUARua Gold 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest PMN, EMH, RUA, and IGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026PMNPromis Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026PMNPromis Neurosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/8/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/20/2026PMNPromis Neurosciences Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64IGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89PMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/ARUARua GoldN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/AN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/A-C$0.08N/AN/AN/AN/AN/AN/AN/APMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)RUARua GoldN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest PMN, EMH, RUA, and IGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ARUARua GoldN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61IGXIntelGenx Technologies164.622.772.69PMNPromis NeurosciencesN/A9.929.92RUARua GoldN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/AIGXIntelGenx TechnologiesN/APMNPromis Neurosciences50.13%RUARua Gold4.14%Insider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/AIGXIntelGenx TechnologiesN/APMNPromis Neurosciences1.50%RUARua GoldN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableIGXIntelGenx Technologies2,050150.55 millionN/ANot OptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableRUARua GoldN/A84.13 millionN/AN/APMN, EMH, RUA, and IGX HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, EMH, RUA, and IGX Company DescriptionsEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.IntelGenx Technologies CVE:IGXC$0.58 +0.01 (+1.75%) As of 10/6/2021IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Promis Neurosciences NASDAQ:PMN$10.68 +0.14 (+1.33%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$10.34 -0.34 (-3.19%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Rua Gold CVE:RUAC$1.33 +0.06 (+4.72%) As of 02/13/2026 More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
